Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.39 |
| ▸ | ECE1 | P42892 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13447538 | 1.00 | GRIK1 (0.39) | GRIK1GRIK2ECE1CTSKMEN1 | |
| SCHEMBL1709871 | 0.84 | GRIK1 (0.37) | GRIK1GRIK2ECE1 | |
| SCHEMBL13540707 | 0.84 | GRIK1 (0.37) | GRIK1GRIK2ECE1 | |
| SCHEMBL17920045 | 0.84 | GRIK1 (0.37) | GRIK1GRIK2ECE1 | |
| SCHEMBL15909791 | 0.84 | GRIK1 (0.37) | GRIK1GRIK2ECE1 | |
| SCHEMBL14852861 | 0.84 | GRIK1 (0.37) | GRIK1GRIK2ECE1 | |
| SCHEMBL22500687 | 0.81 | GRIK1 (0.40) | GRIK1GRIK2CTSKCYP1A2 | |
| SCHEMBL22500689 | 0.81 | GRIK1 (0.40) | GRIK1GRIK2CTSKCYP1A2 | |
| SCHEMBL18701281 | 0.81 | GRIK1 (0.40) | GRIK1GRIK2ECE1CTSKMEN1 | |
| SCHEMBL10280918 | 0.80 | GRIK1 (0.34) | GRIK1GRIK2CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541053-B2 | Methods and compositions for the treatment of hair loss | Aneira Pharma, Inc. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210299023-A1 | COMPOSITIONS AND METHODS FOR HAIR GROWTH | ALLERGAN INC (US) | 2021-09-30 | — | — | US | disclosed |
| US-20210236490-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HAIR LOSS | Aneira Pharma, Inc. (US) | 2021-08-05 | — | — | US | disclosed |
| US-10993944-B2 | Methods and compositions for the treatment of hair loss | Aneira Pharma, Inc. (US) | 2021-05-04 | — | — | US | disclosed |
| US-10987355-B2 | Methods and compositions for the treatment of hair loss | Aneira Pharma, Inc. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20210038601-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HAIR LOSS | Aneira Pharma, Inc. (US) | 2021-02-11 | — | — | US | disclosed |
| US-20180078606-A1 | METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS | SAINT REGIS MOHAWK TRIBE | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180078606-A1 | METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS | IL2, MALT1, CHP1 | GRIK1 4176/4885GRIK2 4159/4885ECE1 2792/4885 |
| US-20210299023-A1 | COMPOSITIONS AND METHODS FOR HAIR GROWTH | CYP21A2, CYP2A7, PPP3R1 | GRIK1 4489/4885GRIK2 4442/4885ECE1 4385/4885 |
| US-10987355-B2 | Methods and compositions for the treatment of hair loss | COXFA4L2, UNG, TYR | GRIK1 4104/4885GRIK2 4216/4885ECE1 4481/4885 |
| US-11541053-B2 | Methods and compositions for the treatment of hair loss | COXFA4L2, UNG, TYR | GRIK1 4104/4885GRIK2 4216/4885ECE1 4481/4885 |
| US-10993944-B2 | Methods and compositions for the treatment of hair loss | COXFA4L2, UNG, TYR | GRIK1 4104/4885GRIK2 4216/4885ECE1 4481/4885 |
| US-20210236490-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HAIR LOSS | COXFA4L2, UNG, TYR | GRIK1 4104/4885GRIK2 4216/4885ECE1 4481/4885 |
| US-20210038601-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HAIR LOSS | COXFA4L2, UNG, TYR | GRIK1 4104/4885GRIK2 4216/4885ECE1 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.